Rosalind Advisors, Inc. — 13F Holdings & Portfolio
CIK 1622627 · latest 13F-HR filed 2026-08-14
Rosalind Advisors, Inc. manages $269.2M in 13F-reported U.S. long-equity assets across 35 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are DCTH (15.44%), FENC (12.73%), XERS (8.56%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 6; 15 existing positions rose in reported value and 8 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- FENNEC PHARMACEUTICALS INC$16.4M +91.6%
- DELCATH SYSTEMS, INC.$10.9M +35.7%
- CYBIN INC$5.6M +75.9%
- XERIS BIOPHARMA HOLDINGS INC$4.3M +22.9%
- VERASTEM INC$3.9M +34.4%
Top Trims
- VAXCYTE INC-$5.2M -31.0%
- INSPIREMD INC-$3.6M -57.0%
- CELLDEX THERAPEUTICS INC-$3.0M -28.9%
- BIOCRYST PHARMACEUTICALS INC-$1.6M -17.9%
- ATEA PHARMACEUTICALS INC-$1.3M -21.0%
Exited Positions
- CG ONCOLOGY INC$6.8M
- VIRIDIAN THERAPEUTICS INC$4.9M
- DEFINIUM THERAPEUTICS INC$2.4M
- LIPOCINE INC$1.8M
- AVALO THERAPEUTICS INC$1.1M
Rosalind Advisors, Inc. Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | DELCATH SYSTEMS, INC. | DCTH | 24661P807 | $41.6M | 15.44% | 3,300,389 | SH |
| 2 | FENNEC PHARMACEUTICALS INC | FENC | 31447P100 | $34.3M | 12.73% | 3,188,001 | SH |
| 3 | XERIS BIOPHARMA HOLDINGS INC | XERS | 98422E103 | $23.0M | 8.56% | 2,908,981 | SH |
| 4 | SAVARA INC | SVRA | 805111101 | $19.6M | 7.27% | 3,178,121 | SH |
| 5 | VERASTEM INC | VSTM | 92337C203 | $15.2M | 5.66% | 3,986,509 | SH |
| 6 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $15.0M | 5.58% | 3,214,766 | SH |
| 7 | EYEPOINT PHARMACEUTICALS INC | EYPT | 30233G209 | $14.1M | 5.25% | 988,230 | SH |
| 8 | CYBIN INC | HELP | 23256X407 | $12.9M | 4.80% | 1,956,814 | SH |
| 9 | VOR BIOPHARMA INC | VOR | 929033207 | $11.9M | 4.44% | 648,600 | SH |
| 10 | VAXCYTE INC | PCVX | 92243G108 | $11.6M | 4.32% | 200,000 | SH |
| 11 | MEDIWOUND LTD | MDWD | M68830112 | $11.0M | 4.09% | 749,054 | SH |
| 12 | CELLDEX THERAPEUTICS INC | CLDX | 15117B202 | $7.4M | 2.76% | 200,000 | SH |
| 13 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $7.2M | 2.68% | 721,504 | SH |
| 14 | PROFOUND MEDICAL CORP | PROF | 74319B502 | $5.5M | 2.05% | 828,118 | SH |
| 15 | TALPHERA INC | TLPH | 00444T209 | $5.3M | 1.98% | 5,169,501 | SH |
| 16 | ATEA PHARMACEUTICALS INC | AVIR | 04683R106 | $5.0M | 1.85% | 1,070,550 | SH |
| 17 | MYOMO INC | MYO | 62857J201 | $3.8M | 1.41% | 3,637,886 | SH |
| 18 | OVID THERAPEUTICS INC | OVID | 690469101 | $3.0M | 1.11% | 1,107,994 | SH |
| 19 | NEURAXIS INC | NRXS | 64134X201 | $3.0M | 1.10% | 508,055 | SH |
| 20 | ABIVAX SA | ABVX | 00370M103 | $2.8M | 1.03% | 20,869 | SH |
| 21 | INSPIREMD INC | NSPR | 45779A846 | $2.7M | 1.02% | 3,905,743 | SH |
| 22 | REGENTIS BIOMATERIALS LTD | RGNT | M8211G108 | $2.5M | 0.92% | 701,685 | SH |
| 23 | SELLAS LIFE SCIENCES GROUP INC Put | SLS | 81642T959 | $2.3M | 0.86% | 568,700 | SH |
| 24 | POLYPID LTD | PYPD | M8001Q126 | $2.0M | 0.73% | 389,455 | SH |
| 25 | BIOFRONTERA INC | BFRI | 09077D209 | $1.2M | 0.45% | 1,275,609 | SH |
| 26 | KURA ONCOLOGY INC | KURA | 50127T109 | $1.1M | 0.41% | 100,000 | SH |
| 27 | SPRUCE BIOSCIENCES INC | SPRB | 85209E208 | $1.1M | 0.40% | 20,000 | SH |
| 28 | AQUESTIVE THERAPEUTICS INC | AQST | 03843E104 | $1.0M | 0.39% | 250,000 | SH |
| 29 | ONKURE THERAPEUTICS INC | OKUR | 68277Q105 | $684.0K | 0.25% | 150,000 | SH |
| 30 | PEPGEN INC | PEPG | 713317105 | $630.0K | 0.23% | 350,000 | SH |
| 31 | CG ONCOLOGY INC Call | CGON | 156944900 | $375.1K | 0.14% | 31,000 | SH |
| 32 | EYEPOINT PHARMACEUTICALS INC Call | EYPT | 30233G909 | $130.8K | 0.05% | 50,300 | SH |
| 33 | ISHARES TR Put | IFXAF | 464287955 | $110.0K | 0.04% | 500,000 | SH |
| 34 | SPDR SERIES TRUST Put | NZUS | 78464A950 | $35.1K | 0.01% | 140,600 | SH |
| 35 | TENAX THERAPEUTICS INC Put | TENX | 88032L955 | $13.9K | 0.01% | 6,200 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $269.2M | 35 | 0001622627-26-000022 |
| 2026-03-31 | 2026-05-14 | $248.9M | 38 | 0001622627-26-000015 |
| 2025-12-31 | 2026-02-12 | $284.5M | 42 | 0001622627-26-000011 |
| 2025-09-30 | 2025-11-13 | $292.6M | 39 | 0001622627-25-000038 |
SUITE 326
TORONTO M4Y 0G7